Skip to content

Quality Control of CE-Certified Phonak Hearing Aids - 2019_34

Quality Control of CE-Certified Phonak Hearing Aids - 2019_34

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04187781
Enrollment
13
Registered
2019-12-05
Start date
2019-11-11
Completion date
2020-01-17
Last updated
2020-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Brief summary

Phonak Hearing Devices pass through different development and study phases. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, resulting from the pre-validation studies, they get optimized. Prior to product launch, the Phonak Hearing Systems get reviewed by a final quality control in terms of clinical trials. This is a validation study, investigating improved algorithms, features, functions and wearing comfort. This will be a clinical investigation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

Detailed description

This study will compare two settings of an external microphone under real life conditions with experienced hearing aid users. The external microphone streams the signal (e.g. speaker) directly into the hearing instrument (HI). The subject should rate the devices in the lab and after a hometrial. The comfort, regarding to the loudness and the sound quality will be tested with the two settings at home and in the lab. Also the speech intelligibility will be tested in the lab. This will be a clinical investigation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

Interventions

DEVICEexternal microphone

External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.

Sponsors

Sonova AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* experienced hearing aid user * severe hearing loss * willingness and interest in testing an external microphone healthy outer ear * willingness to wear behind the ear hearing aids * Informed Consent as documented by signature

Exclusion criteria

* the audiogram is not in the fitting range of the intended hearing aid * limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland) * participant is not able to describe experiences and hearing impressions

Design outcomes

Primary

MeasureTime frameDescription
Rating of the subjective comfort for the old and the new setting6 weeksRating of the comfort, regarding to the loudness, with the old and the new setting of the external microphone (%)

Secondary

MeasureTime frameDescription
Evaluation of the speech intelligibility in noise2 weeksAnother Outcome measure of this study is the Evaluation of speech understanding in noise of the device with the old setting and the new setting. Speech understanding in noise will be evaluated with an objective and validated test procedure, the Outcome measure will be the speech intelligibility in %.
Subjective Sound Quality rating6 weeksThe secondary Outcome measure of this study is the Evaluation of the perceived Sound Quality (rated via subjective satisfaction rating) of the signal with the old setting, compared to the new setting of the external microphone.
Subjective rating of natural sounds6 weeksThe subject should rate in the hometrial how natural environmental sounds are with the hearing aids.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026